ASCO 2024 - Complete program listing (16 programs)

Created by oncoXchange

June 2024



Entire series of daily recaps and interviews from the 5 days of ASCO 2024 from June 1st to the 5th


Advancements in Breast Cancer Research: Insights from Dr. Shaheena DawoodDr. Shaheena Dawood shares her excitement about the wealth of information related to patients with breast cancer and how this data will impact clinical practice. In particular, she highlights three crucial pieces of information from ASCO and reviews data from the DESTINY-Breast06 Update, postMONARCH study and updated analysis from the innovaTV207 trial.

Advancements in AI for Breast Cancer ImagingDr. Maryellen Giger discusses the exciting developments in artificial intelligence (AI) applied to breast cancer imaging. From risk assessment to early detection, diagnosis, prognosis, and treatment response, AI is making significant strides

PALMARES-2 Study: Real-World Insights on CDK4/6 InhibitorsExplore the findings of the PALMARES-2 study with Dr. Claudio Vernieri, offering crucial real-world insights into the efficacy of CDK4/6 inhibitors. Learn how these insights aid clinicians and patients in making informed treatment decisions for specific clinical settings.

Novel Additions to Breast Cancer Therapy: Insights from Dr. Laura Stewart DominiciDr. Dominici Chairs ASCO’s ‘Breast Cancer Local/Regional/Adjuvant’ therapy session where 9 abstracts covered a number of different topics, three of which look at some interesting additions to standard therapy.

ASCO 2024 - MedTalk: Dr. Stephanie Wong on PARPi Eligibility in Women with Newly Diagnosed Invasive Breast CancerJoin Dr. Stephanie Wong at ASCO as she presents data on PARP inhibitor eligibility in women with newly diagnosed invasive breast cancer. This research is part of the GREAT AGATA Study, a universal genetic testing initiative aimed at improving patient outcomes.

ASCO 2024 - Global Speaker Series: Dr. Judy-Anne Williams Chapman on Standardizing ER and PgR Quantitation in Breast CancerDr. Judy-Anne Williams Chapman, PhD, emphasizes her four decades of work on the critical topic of estrogen and progesterone receptors. She proposes an adjunctive statistical standardization of quantitated ER and PgR to enhance inter-laboratory comparability of biomarker results and improve the therapeutic management of breast cancer.


Daily RECAP day 2Join Dr. Jamil Asselah and Dr. Kim Ma, along with Dr. Véronique Diéras, as they review the day's highlights with a special focus on the positive findings from the DESTINY-Breast06 trial. They will discuss how these results are set to impact clinical practice, particularly for patients with HER2-ultralow breast cancer, and delve into all aspects of T-DXd in treatment strategies.

ASCO 2024 - Dr. Mark Basik Highlights TRICIA Study Results in Triple Negative Breast CancerJoin Dr. Mark Basik as he presents the results of the TRICIA study, conducted across cancer centers and hospitals in Quebec and Ontario. Learn about the significant findings and the plans to initiate a clinical trial in the coming years, with the goal of advancing treatment options for this challenging type of cancer.

ASCO 2024 - Dr. Nagi S. El Saghir on New Advances in Sequencing CDK4/6 Inhibitors with Endocrine Therapy in Advanced Breast CancerJoin Dr. Nagi S. El Saghir as he discusses new studies presented at ASCO 2024. He highlights recent studies on the sequencing of CDK4/6 inhibitors and endocrine therapy in patients with advanced breast cancer.

ASCO 2024 - Dr. Jean-Pierre Ayoub Reviews DESTINY-Breast06: Trastuzumab Deruxtecan's Impact on Progression-Free SurvivalJoin Dr. Jean-Pierre Ayoub as he reviews important results from the DESTINY-Breast06 trial. Learn how Trastuzumab Deruxtecan significantly improves progression-free survival in breast cancer patients previously treated with endocrine therapy. Discover the potential implications of these findings for patient care and treatment strategies.

ASCO 2024 - Dr. Matthew P. Goetz on the ELAINE 3 Study: Lasofoxifene and Abemaciclib in ER+/HER2- Advanced Breast CancerJoin Dr. Matthew P. Goetz as he discusses the open-label, randomized, multicenter phase 3 ELAINE 3 study. This research investigates the efficacy and safety of lasofoxifene combined with abemaciclib for treating ER+/HER2- locally advanced or metastatic breast cancer with an ESR1 mutation. Discover the potential impact of these findings on patient care and treatment options.

ASCO 2024 - Dr. Jane Lowe Meisel Presents I-SPY2.2 Trial Results on Datopotamab Deruxtecan for High-Risk HER2-Negative Breast CancerJoin Dr. Jane Lowe Meisel as she presents the first results from the I-SPY2.2 trial at ASCO. This study explores the use of datopotamab deruxtecan as part of neoadjuvant therapy for high-risk, HER2-negative early-stage breast cancer.


ay 1 Highlights of ASCO: Drs. Asselah and Ma Review key takeawaysJoin Drs. Asselah and Ma as they review the key takeaways from Day 1 of ASCO. They delve into hormone-positive disease, discuss notable abstracts, and provide insights on the Flex trial registry. Hear about Dr. Grace Choong’s research from Mayo Clinic on endocrine therapy for ER-low breast cancer patients. Stay tuned for what to expect in the days ahead at the conference.Dr. Santa Maria on the Benefit of Early PET Scan Changes inTriple Negative Breast CancerJoin Dr. Santa Maria as he discusses his current project exploring the use of chemotherapy combined with immunotherapy in patients with stage 2 and 3 triple-negative breast cancer. Learn how early PET scan changes are being used to identify patients who achieve a complete pathologic response earlier in the treatment process.Dr. Pier Franco Conte on the A-BRAVE Trial: Avelumab in Early Triple-Negative Breast CancerJoin Dr. Pier Franco Conte as he discusses the A-BRAVE trial, a Phase III randomized study exploring the use of avelumab in early triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy or those at high risk following primary surgery and adjuvant chemotherapy.De-escalation studies: The next step in early breast cancerWatch Dr. Carlos A. Gonzalez Nuñez discuss 'De-escalation studies: The Next Step in Early Breast Cancer' in this brief video from the ASCO Meeting.